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Objectives: The goal of this study was to evaluate the early results of fenestrated endovascular aortic repair (f-EVAR) using custom-made stent graft (CMSG) or physician-modified stent graft (PMSG) to revascularize the visceral artery for the patients with abdominal aortic aneurysm (AAA) or dissection involving visceral artery.
Methods: We evaluated the early results of fenestrated endovascular aortic repair (f-EVAR) using custom-made stent graft (CMSG) or physician-modified stent graft (PMSG) to revascularize the visceral artery for the patients with AAA or dissection involving visceral artery.
Results: The median patient age was 67 years (range, 49-75 years), and seven of the nine patients (77.78%) were men. One CMSG and eight PMSGs were deployed. Indications were AAA with short infrarenal proximal landing zone (n ¼ 8) and chronic dissection involving visceral arteries (n ¼ 1). Twenty-two visceral arteries were revascularized (15 renal arteries, 6 superior mesenteric arteries, 1 celiac artery). Median duration for stent graft modifications was 55 minutes (range, 30-75 minutes) . PMSGs with 1 fenestration were deployed for 2 patients, 1 fenestration combined with 1 scallop for 1 case, 2 fenestrations for 1 case, 2 fenestrations combined with 1 scallop for 4 cases, and 4 fenestrations for 1 case. Primary technical success rate was 88.89% (8 of 9). One type III endoleak occurred. Mean operative time was 181 6 45 minutes, and fluoroscopy time was 45 6 28 minutes. There were no in-hospital deaths and no perioperative mesenteric ischemia complications. Median length of postoperative stay was 10 6 6 days (range, 7-28 days). Renal dysfunction occurred in three cases during 7 postoperative days and improved with medical treatment. Mean follow-up period was 8.6 months (range, 1-24 months). The Doppler follow-up for two cases with renal dysfunction at 3 months showed no endoleak and patency of PMSG and branch stent graft. Computed tomography angiography was performed for other seven cases postoperatively. One branch stent graft was found occluded at 6 months. Patency and no endoleak of fenestrated stent graft and branch stent grafts were found from the images of another six cases.
Conclusions: F-EVAR with PMSG may be a viable alternative for patients with AAA or dissection involving visceral artery and unable to wait for CMSG. Objectives: Endovascular aneurysm repair has been shown to reduce mortality in the emergent repair of ruptured abdominal aortic aneurysms (AAA). However, long-term survival data for this group of patients are lacking with contemporary endovascular endografts. The purpose of this study was to evaluate 30-day mortality rates and 1-year survival in patients undergoing emergent EVAR in a 43-facility hospital system with a quaternary referral center with an established ruptured aneurysm protocol.
Methods: This was a retrospective analysis of patients captured prospectively in an Institutional Review Board-approved registry for patients treated emergently for AAA 2012 and 2017. Primary outcome measures were 30-day mortality and 1-year survival for the entire group, as well as for symptomatic and ruptured aneurysms. Data were analyzed using logistic regression survival curves, and a log-rank test was performed to compare survival between open and endovascular repair. Patients were evaluated on an intent-to-treat basis and outcomes evaluated in a multivariate model.
Results: A total of 249 patients were referred as part of the protocol. Of these, 102 (41%) were treated emergently. The 30-day and 1-year survival was 63% and 42% for all patients, 58% and 37% for ruptured patients, and 85% and 62% for symptomatic patients (Fig) . EVAR resulted in improved 30-day (64% vs 31%; odds ratio, 4.0; P ¼ .03) and 1-year survival (40% vs 23%; odds ratio, 2.3; P ¼ .35) over open repair. Significant predictors for 30-day mortality included hypotension (P ¼ .0003), blood transfusion (P < .0001), length of stay (P ¼ .0005), extravasation (P ¼ .01), preoperative cardiopulmonary resuscitation (P ¼ .04), open repair (P ¼ .0068), aortouniiliac reconstruction (P ¼ .0079), and abdominal compartment syndrome (P ¼ .0067). Significant predictors for 1-year mortality included advanced age (P ¼ .04), hypotension (P ¼ .01), blood transfusion (P ¼ .006), extravasation (P ¼ .03), reintubation (P ¼ .03), and abdominal compartment syndrome (P ¼ .03). There were no differences in outcomes based on race, gender, or outside transfer. Peripheral arterial disease (P ¼ .04), hypertension (P ¼ .04), coronary artery disease (P ¼ .03), and familial history (P ¼ .05) of aneurysms was related to increased 30-day mortality. Peripheral arterial disease (P ¼ .059) and coronary artery disease (P ¼ .067) were nearly significant, with increased 1-year mortality.
Conclusions: EVAR is associated with improved survival compared to open repair in patients requiring emergent AAA repair. However, in the first year, there is a significant risk of death based on initial presentation, as well as underlying comorbidities. To improve long-term survival, aggressive medical management and medical surveillance is warranted.
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IP097. EVAR With Contemporary Volume-Dependent Sac Embolization Compared to Endovascular Aneurysm Sealing System (EVAS) in the Prevention of Type II Endoleak and Its Complications
Methods: This retrospective study included patients with abdominal aortic aneurysm elected for EVAR and identified as "at risk" for ELII in two vascular centers between 2014 and 2016. The definition "at risk" for ELII was patency of inferior mesenteric artery (IMA) with >3 mm diameter; patency of at least three pairs of lumbar arteries, or two pairs of lumbar arteries plus sacral artery or accessory renal artery or any diameter patent IMA. EVAS was performed according to device instructions for use. Overall, 130 patients underwent endovascular repair (Embo-EVAR, n ¼ 75 [57.7%]; EVAS, n ¼ 55 [42.3%]). ELII rates during follow-up were compared. Freedom from any reintervention and freedom from ELII-related reintervention were compared using Kaplan-Meier estimates.
Results: Patient characteristics and Society for Vascular Surgery comorbidity scores (0.93 6 0.53 vs 0.93 6 0.52; P ¼ 1.00) as also mean aneurysm sac diameter (61 6 13 vs 57 6 8 mm; P ¼ .05) and mean sac patent lumen diameter (43 6 10 vs 45 6 9 mm; P ¼ .24) were similar between Embo-EVAR and EVAS. However, Embo-EVAR had a significantly higher number of cases with aneurysm sac patent lumen diameter >60 mm compared to EVAS (8% vs 0%; P ¼ .03). Operative time (151 6 37 vs 115 6 23 minutes; P < .001) and length of hospitalization (4.0 6 4.6 vs 2.9 6 1.8 days; P ¼ .02) were longer in Embo-EVAR compared to EVAS. Freedom from ELII was lower in Embo-EVAR at 3 months (92% vs 100%; P ¼ .04), but was similar between Embo-EVAR and EVAS at 6 (93% vs 98%; P ¼ .40), 12 (90% vs 98%; P ¼ .27), and 24 months (100% vs 100%; P ¼ 1.00). At 24 months freedom from any reintervention (Embo-EVAR, 98% vs EVAS; 95%; P ¼ .19) and freedom from ELII-related reintervention were similar (100% for both groups; P ¼ 1.00). Within Embo-EVAR, ELII-related reintervention was 0% both for patients with <60 mm and >60 mm sac patent lumen (P ¼ .1).
Conclusions: EVAS compared to Embo-EVAR is associated to shorter operative time and length of hospitalization. Although further confirmatory studies are needed, both Embo-EVAR and EVAS seem to be associated to a low rate of ELII and EIIerelated reintervention over the midterm follow-up. Embo-EVAR may be a valid alternative for prevention of EII-complications, also for large aneurysm with a sac patent lumen diameter > 60 mm.
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